ReCode Therapeutics, a clinical-stage genetic medicines company using tissue-specific delivery to power the next wave of mRNA and gene correction therapeutics, today announced that company management will participate in the upcoming May conferences:
Wells Fargo Virtual Private Biotech Symposium
Format: 1x1 Investor Meetings
Date: May 6, 2024
Location: Virtual
Capital One Biotech - Life Sciences Disruptors Event
Format: Panel Discussion on “The Next Wave of mRNA and Gene Correction Therapeutics”
Date: May 14, 2024
Time: 1:45 p.m. ET
Location: New York
Virtual Piper Sandler Lung Day Post-ATS
Format: Fireside Chat
Date: May 23, 2024
Time: 12:00 – 12:25 p.m. ET
Location: Virtual
About ReCode Therapeutics
ReCode Therapeutics is a clinical-stage genetic medicines company using precision delivery to power the next wave of mRNA and gene correction therapeutics. ReCode’s proprietary Selective Organ Targeting (SORT) lipid nanoparticle (LNP) platform enables highly precise and targeted delivery of genetic medicines directly to the organs, tissues and cells implicated in disease, enabling improved efficacy and potency. ReCode’s lead programs include RCT1100 for the treatment of primary ciliary dyskinesia caused by pathogenic mutations in the DNAI1 gene, and RCT2100 for the treatment of the 10-13% of cystic fibrosis patients who have Class I mutations in the CFTR gene and do not respond to currently approved CFTR modulators. RCT1100 and RCT2100 are inhaled disease-modifying mRNA-based therapies formulated using the SORT LNP delivery platform. ReCode is expanding its pipeline to develop potential therapies for other rare and common genetic diseases, including musculoskeletal, central nervous system, liver and infectious disease indications.
ReCode has been recognized by the San Francisco Business Times and Silicon Valley Business Journal as a Best Place to Work. For more information, visit www.recodetx.com and follow us on LinkedIn and Instagram.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240501402596/en/
Contacts
Investor Contact:
Anne Marie Fields
Stern IR
annemarie.fields@sternir.com
IR@recodetx.com
Media Contacts:
Erica Jefferson
SVP, Corporate Affairs
ReCode Therapeutics
ejefferson@recodetx.com
650-629-7965
Tara Cooper
The Grace Group
tara@gracegroup.us
650-303-7306
